April 22, 2008 - ... Biocon commences Phase IIa Clinical Trials for IN105 : An open label, multi-centric, placebo controlled, single ascending dose study designed to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of IN105 under fed conditions in type II diabetic patients currently on Metformin therapy has been commenced at 5 investigation sites. The study is expected to be completed in August 2008 and will provide the data necessary to commence Phase IIb clinical trials... Biocon's Press Release -
Monday, May 5, 2008
Biocon Limited : Phase IIa Clinical Trials for IN105
April 22, 2008 - ... Biocon commences Phase IIa Clinical Trials for IN105 : An open label, multi-centric, placebo controlled, single ascending dose study designed to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of IN105 under fed conditions in type II diabetic patients currently on Metformin therapy has been commenced at 5 investigation sites. The study is expected to be completed in August 2008 and will provide the data necessary to commence Phase IIb clinical trials... Biocon's Press Release -
